908 KAR 1:340. Narcotic treatment
programs.
RELATES TO: KRS 218A.180, Chapter 222,
315.020, 42 C.F.R. Part 8
STATUTORY AUTHORITY: KRS 194A.030,
194A.050, 222.231, 42 C.F.R. Part 8, EO 2004-726
NECESSITY, FUNCTION, AND CONFORMITY: EO 2004-726,
effective July 9, 2004, reorganized the Cabinet for Health Services and placed
the Department for Mental Health and Mental Retardation within the cabinet. KRS 194A.050 and 222.231
authorize the Cabinet for Health and Family Services to establish guidelines
and provide for the systematic evaluation of effectiveness of narcotic
treatment programs. This administrative regulation establishes the State
Narcotic Authority with the Division of Substance Abuse, within the Department
for Mental Health and Mental Retardation Services, and establishes licensure
and operations requirements for narcotic treatment programs.
Section 1. Definitions. (1)
"Administrative detoxification" means the detoxification from the
approved controlled substance for the safety and well being of the client,
other clients, and staff of the narcotic treatment program.
(2) "Approved controlled
substance" means the drugs methadone except for powdered methadone, or
ORLAAM used in the treatment of narcotic addiction.
(3) "CHS or cabinet" means the
Cabinet For Health Services.
(4) "Client" means any
individual who receives a controlled substance for the purpose of maintenance
or detoxification in an NTP.
(5) "CSAT means the Center for
Substance Abuse Treatment.
(6) DEA" means the Drug Enforcement
Administration.
(7) "Dose" means a one (1) day
quantity of an approved controlled substance, administered on site, in not less
than one (1) fluid ounce of an oral solution, formulated to minimize misuse by
injection.
(8) "Drug screening" means the
process by which a program determines the presence or the absence of drugs in
the body fluids.
(9) "Main program" means the
location where all administrative and medical information related to the
narcotic treatment program is retained for the purpose of on-site reviews by
federal agencies or the state narcotic authority.
(10) "Medication station" means
any dosing location that obtains its drug supply from the main program site and
retains all records (except dosing, urine screens) at the main location.
(11) "Narcotic detoxification
program" means a program using approved controlled substances in
continually reducing dosages over a period of time for the purpose of relieving
or reducing withdrawal symptoms.
(12) "Narcotic maintenance"
means a treatment procedure using an approved controlled substance over a
period of time to relieve withdrawal symptoms, reduce narcotic craving, and
permit normal functioning so that, in combination with rehabilitation services,
clients can develop a productive lifestyle.
(13) "Narcotic treatment
program" or "NTP" means a substance abuse program using approved
controlled substances and offering a range of treatment procedures and services
for the rehabilitation of persons dependent on opium, morphine, heroin or any
derivative or synthetic drug of that group.
(14) "ORLAAM" means a brand of
levomethadyl acetate hydrochloride; levo-alpha-acetylmethadol hydrochloride.
(15) "Phase treatment" means
the client's progress through treatment in a graduated sequence system.
(16) "Program sponsor" means a
person or representative of an individual or entity who assumes
responsibilities for the operation of a narcotic treatment program and for the
on-site conduct of all employees, and other persons providing services, and
ensures that the program is operated in compliance with this administrative
regulation.
(17) "Proposed program" means
an individual or entity in the process of seeking a narcotic treatment license.
(18) "Public health director"
means the director of the local public health department.
(19) "SNA" means the State
Narcotic Authority.
(20) "Take-home dose" means a
quantity of an approved controlled substance which the client is eligible to
take off site.
(21) "Voluntary detoxification"
means a client requested, physician supervised withdrawal from the approved
controlled substance.
Section 2. State Narcotic Authority. The
SNA shall be the Director, Division of Substance Abuse, within the Department
for Mental Health and Mental Retardation Services.
Section 3. Ordering of an Approved
Controlled Substance. Programs shall order approved controlled substances from
the manufacturer by submitting the Federal Form 222. The program sponsor or
designee shall complete Form 222.
Section 4. Application to Operate a NTP.
(1) A proposed program desiring to operate a NTP shall meet the requirements of
this administrative regulation, and shall be licensed in accordance with KRS
222.231(12) and 908 KAR 1:370 prior to application.
(2) The proposed program shall submit
each staff member’s, including the program sponsor, administrator, and all
other personnel, profile and resume of educational and professional experience,
including Social Security numbers and date of birth.
(a) If the program is a corporation or
partnership, the application shall list all partners’ and members' names,
addresses, dates of birth, and Social Security numbers.
(b) Failure to provide this information
shall disqualify the application for further review.
(3) The proposed program shall submit or
cause to be submitted on its behalf to the SNA a written protocol which shall
serve as an application for licensure by the SNA. This protocol shall include
the following:
(a) A plan of operation;
(b) A description of the geographic area
to be served by the program;
(c) Population and area to be served;
(d) The estimated number of persons, in
the described area, addicted to heroin or other morphine-like drugs and an
explanation of the basis of the estimate;
(e) The estimated number of persons in
the described area addicted to heroin or other morphine-like drugs presently
under treatment in methadone and other treatment programs;
(f) The number of patients in narcotic
treatment, projected rate of intake, and factors controlling projected intake;
(g) Program goal;
(h) Plan for evaluation;
(i) Memoranda of agreement which reflect
supportive services from the administrative head of the following agencies:
1. Hospitals;
2. Local law enforcement including jails;
3. Community mental health and mental
retardation agencies;
4. Private, for-profit alcohol and drug
services and publicly funded alcohol and drug services;
5. Department of Vocational
Rehabilitation Services; and
6. Private, for-profit mental health
counseling services;
(j) Client identification system;
(k) System to prevent client’s multiple
program registration;
(l) Organizational chart which includes
the persons responsible for the program;
(m) First year budget, which list
available, pending, or projected funds;
(n) Copies of letters verifying funding;
(o) Schedule of the amount of the client
fees;
(p) Duties and responsibilities of each
staff member and the relationship between the staffing pattern and the
treatment goals;
(q) Duties and responsibilities of the
medical director;
(r) Plan for delegation of the medical
director’s duties, if appropriate;
(s) Training and experience of counselors
and therapists;
(t) Counselor and therapist caseload;
(u) Procedures and criteria for client
selection;
(v) Program rules and instructions;
(w) Facility description;
(x) Initial dosage levels;
(y) Daily dosage levels;
(z) Operational procedures including the
procedures to be used in inventory maintenance and daily dosing schedules;
(aa) Procedures, or documented efforts
made, which provide for cooperation with local jails and hospitals for either
withdrawal or maintenance while in custody or hospitalized in the event of
client incarceration or hospitalization;
(bb) Procedures in the event of state or
national or manmade emergency or disaster.
(cc) Urinalysis procedures which utilize
random selection or unannounced collection;
(dd) Procedures for scheduled
termination, voluntary termination, and involuntary termination for cause,
including reasons for termination for cause;
(ee) Fair hearing procedures for client
grievances;
(ff) Copies of all forms developed and to
be used by the proposed NTP;
(gg) Facility address and dimensions;
(hh) Amount of space devoted to methadone
treatment, including waiting, counseling, dispensing, and storage areas;
(ii) Days and hours of dispensing;
(jj) Days and hours of other program
services;
(kk) Type of services provided and the
hours of use, if the facility is also used for purposes other than narcotic
treatment; and
(ll) Diagram of the facility housing the
NTP and an accompanying narrative which describes client flow. The diagram and
narrative shall specify:
1. Waiting areas;
2. Office space;
3. Dispensing area;
4. Urine collection locations;
5. Record storage area;
6. Parking or transportation access; and
7. The relation of the services to the
facility diagram.
(4) A protocol proposing a new program or
a complete revision of the protocol of an approved program shall be submitted
to the SNA.
(5) The proposed program shall submit
written policies and procedures in accordance with Sections 6, 7, 8, 9, 10, 11,
12, 13, 14 and 16 of this administrative regulation.
Section 5. SNA Application Review
Process. (1) The SNA shall review the application materials within thirty (30)
working days for the following:
(a) Criminal convictions by all
individuals or entities involved with the proposed program within the past five
(5) years, including violations of controlled substance laws and administrative
regulations;
(b) Suspension or revocation of any CSAT,
DEA, state narcotic licenses, or professional licenses in the past five (5)
years of any staff member including the medical director, registered nurses,
licensed practical nurses and registered pharmacist; and
(c) The written monitoring reports and
compliance reports of other NTPs currently operated by the applicant or by any
corporation or partnership with whom the applicant has been associated in the
past five (5) years. These reports shall be obtained from the DEA and CSAT
agents, medical licensing boards, pharmacy licensing boards, nursing licensing
boards, and from other SNAs.
(2) The SNA shall not grant an
application to operate a NTP to any applicant that has employed staff or, if
applicant is a corporation or partnership, any officer of the corporation or
member of the partnership who was convicted of a misdemeanor related to
controlled substances laws or any felony within the last five (5) years.
(3) The SNA shall work in collaboration
with the DEA and CSAT in reviewing the proposed application. Before any narcotic
license shall be issued to the proposed program, the SNA, the DEA office, and
the CSAT office shall all agree.
(4) The SNA shall conduct an on-site
inspection to review the proposed program and interview the medical director,
program sponsor and dosing staff.
(5) The SNA shall not approve any
application for a NTP to any entity that poses a risk to the health and safety
of the public based on a history of noncompliance with state and federal
regulations as verified by the DEA or CSAT or state licensure agencies in
states in which the entity currently legally operates.
(6) The SNA shall respond in writing,
within ten (10) working days, to the proposed program upon receipt of all
reports and documents from the applicant and all agencies involved.
(7) If the application to operate the NTP
is approved the SNA shall, within thirty (30) working days of the completion of
the review process:
(a) Issue a letter, pending receipt of
federal approval, which shall indicate the approval to operate a NTP in Kentucky
and shall include, the DEA license number, the CSAT license number, and the
expiration date of the license to operate; and
(b) Assign a facility responsible for the
distribution of the approved controlled substances to be used in the NTP.
(8) If the application to operate a NTP
is not approved within thirty (30) working days, the SNA shall respond in
writing citing the deficiencies, the requirements and time frames for taking
corrective actions to make the program licensable.
(9) The proposed program shall provide a
plan of correction for deficiencies cited within fifteen (15) working days from
date of receipt of the written deficiencies.
Section 6. Organization and
Administration Policies. (1) NTPs shall develop policies and procedures that
include:
(a) Waiting list criteria;
(b) Criteria for the use of ORLAAM for
clients needing or desiring take-home doses, but who do not meet eligibility
requirements for take-home doses;
(c) Policies pertaining to the
preparation and labeling of client doses which shall include:
1. The quantity of approved controlled
substances that is indicated on the client's narcotic sheet within the medical
record;
2. Assurance that doses shall be labeled
with the exact quantity of narcotic drug ordered;
3. Take-home doses shall be formulated in
such a manner that shall reduce the likelihood of injecting the dose;
4. Policies that permit clients to know
their dose level; and
5. Policies that shall provide for the
packaging of take-home doses of the approved controlled substances in
containers that meet the requirements of 15 U.S.C. 1471. The label of the doses
shall include the name of the program, address and telephone number of the
program, name of the controlled substance, name of the client, the name of the
physician ordering the substance, and the quantity of the controlled substance,
unless the client has requested in writing that the quantity of the substance
not be revealed to them.
(2) The program policies shall indicate
that the medical director or program physician at the individual NTP is in
charge of all dose adjustments.
(3) The program policies shall indicate
that dosing personnel do not alter client doses without the medical director or
program physician’s order.
(4) Verbal dosing orders shall be signed
by the medical director or program physician within forty-eight (48) hours of
the order’s receipt.
(5) The medical record shall indicate any
reason for dose changes and shall be signed by the medical director or program
physician.
(6) Detoxification policies for voluntary
and administrative detoxification shall be in compliance with 42 C.F.R. Part 8,
i.e.: short-term (thirty (30) days or less), or long-term (more than thirty
(30) days and as much as 180 days).
(7) Urine collection policies for drug
screening purposes shall be developed to assure absence of falsification. Each
sample shall be analyzed for the following drugs:
(a) Methadone;
(b) Cocaine;
(c) Opiates;
(d) Amphetamines;
(e) Barbiturates;
(f) Tetrahydrocannabinol;
(g) Benzodiazepines; and
(h) Any other drug(s) that has been
determined by the NTP or the SNA to be abused in that program's locality or any
other drugs that may have been abused by the client.
(8) NTPs shall have policies that
prohibit procedures for offering a bounty, monetary or equipment or merchandise
reward, or free services for individuals in exchange for recruitment of new
clients into the program.
(9) NTPs shall assure compliance with the
system of treatment phases outlined in Section 11 of this administrative
regulation.
(10) NTPs shall develop quality assurance
policies to assure that services provided are achieving beneficial effects for
the clients using the services.
(11) Urine drug screens shall be reviewed
by the treatment team monthly to determine client's reduction in the use of
unauthorized medications.
(12) Controlled substance medications
shall be considered unapproved usage if they are being used by the client
without a valid prescription.
(13) A valid urine drug screen negative
for the approved controlled substances, with the exception of ORLAAM, allowed
to be used in the NTP shall be considered positive for unauthorized drug use.
(14) The NTP shall assure that urine drug
screens are not used as the sole criteria for dismissing clients from the
program.
(15) NTPs shall develop quality assurance
procedures to determine the adequacy of the NTP's organization and service
delivery. The assessment shall:
(a) Examine the content of the NTP's
organizational and administrative structure and shall assess the following:
1. Availability of counseling services;
2. Availability of physical health
services to clients;
3. Vocational training available to
clients;
4. Legal assistance or referral, if
indicated for the client;
5. Americans With Disabilities Act (ADA)
defined accessibility in the on-site programs to the clients;
6. Quality assurance of the program
services; and
7. Continuity of services and care.
(b) Be reviewed semiannually by the
clinical supervisor, medical director, program sponsor, and the dosing nurse
supervisor;
(c) Evaluate the following:
1. Appropriateness of the services
delivered;
2. Completeness of documentation in
client records;
3. Quality of and participation in staff
training programs; and
4. Status of licenses and certification
documents.
(16) All NTPs shall be open for dosing
services seven (7) days a week with the optional exception of the following
holidays:
(a) New Years Day, January 1;
(b) Presidents Day;
(c) Martin Luther King Day;
(d) Easter Sunday;
(e) Memorial Day, last Monday in May;
(f) Independence Day, July 4;
(g) Labor Day, first Monday in September;
(h) Thanksgiving Day, fourth Thursday in
November; and
(i) Christmas Day, December 25.
Section 7. Personnel Policies. (1) The
NTP shall have a program sponsor who shall:
(a) Assure that KRS 222.231, 908 KAR
1:370, 42 C.F.R. Part 8,, KRS Chapter 218A, 902 KAR 55:010 to 55:095 and this
administrative regulation, are followed by the NTP;
(b) Have two (2) years documented
experience in the treatment of addictions. The program sponsor shall be
certified by the Board of Certification of Alcohol and Drug Counselors, or a
physician, nurse, physician assistant, pharmacist, or nurse practitioner
certified by the respective licensing subspecialty, or shall have a minimum of
a masters degree in the field of addictions or related field; and
(c) Assure that clients:
1. Receive and sign written information
describing all facets of the program in a manner that the client understands;
2. Have had the contents of the
"Consent to Treatment with an Approved Narcotic Drug", Form FDA 2635
(7/93), communicated to them and voluntarily sign the consent to treatment;
3. Under eighteen (18) years of age, have
parents or legal guardians of nonemancipated minors sign the consent to treatment;
4. Receive information on communicable
diseases at admission, readmission, and at six (6) month intervals for the
first two (2) years of treatment, and as indicated clinically after two (2)
years. Communicable diseases shall include tuberculosis, hepatitis, sexually
transmitted diseases, and HIV/AIDS; and
5. Receive HIV/AIDS pretest, posttest
counseling, and provide for voluntary HIV testing at admission or when
clinically indicated thereafter.
(2) The program sponsor shall assure:
(a) That professional staff in the NTP
shall maintain current credentials and that professional skills pertinent to
their job descriptions shall be updated annually;
(b) That the laboratory performing the
testing required under this administrative regulation is approved by the SNA,
is certified by the Health Care Financing Administration as a CLIA (Clinical
Laboratory Improvement Act-1988) certified laboratory, has a protocol in place
that assures the integrity of the chain of custody for all urine drug tests,
and an assurance that the initial test and confirmatory tests for drugs tested
on behalf of the program meets the following standards;
1. Marijuana metabolites - initial screen
50ng/ml, confirmation test 15ng/ml;
2. Cocaine metabolites - initial screen
300ng/ml, confirmation test 150ng/ml;
3. Opiates metabolites - initial screen
300ng/ml, confirmation test 300ng/ml;
4. Amphetamines - initial screen
1000ng/ml, confirmation test of amphetamine 500ng/ml, and methamphetamine
confirmation test 500ng/ml;
5. Barbiturates - initial screen
300ng/ml, confirmation test 300ng/ml; and
6. Benzodiazepines - initial screen
300ng/ml, confirmation test 300ng/ml.
(c) That drug test results shall not be
used as the sole criteria for administratively detoxifying a client from the
NTP;
(d) That when drug testing results are
used, presumptive laboratory results shall be distinguished from results that
are definitive;
(e) That urine samples used for drug
screening purposes shall be handled in a manner that ensures client confidentiality;
(f) That client attendance shall not be
revealed to any person or agency without the specific written authorization of
the client, or a valid court order.
(3) NTPs shall have a medical director
who shall:
(a) Be licensed by the Commonwealth of Kentucky
to practice medicine within the Commonwealth and function autonomously within
the NTP free from any protocol imposed by any NTP, sponsor, or any other entity
except under the guidelines imposed by 42 C.F.R. Part 8 and this administrative
regulation; and
(b) Be a board eligible psychiatrist
licensed to practice in Kentucky and have three (3) years documented experience
in the provision of services to persons who are addicted to alcohol or other
drugs; or
(c) Be a physician licensed to practice
in Kentucky and certified as an addictionologist by the American Society of
Addiction Medicine; and
(d) Be responsible for dosing staff in
the NTP and shall be responsible for the NTPs adherence to 42 C.F.R. Part 8,
KRS Chapter 218A, 902 KAR 55:010 to 55:095, 908 KAR 1:370 and this
administrative regulation.
(4) NTPs may have a program physician who
shall:
(a) Be licensed by the Commonwealth of
Kentucky to practice medicine within the Commonwealth and function autonomously
within the NTP free from any protocol imposed by any NTP, sponsor, or any other
entity except under the guidelines imposed by 42 C.F.R. Part 8 and this
administrative regulation; and
(b) Be a board eligible psychiatrist
licensed to practice in Kentucky and have three (3) years documented experience
in the provision of services to persons who are addicted to alcohol or other
drugs; or
(c) Be a physician licensed to practice
in Kentucky and certified as an addictionologist by the American Society of
Addiction Medicine; and
(d) Be responsible for dosing staff in
the NTP and shall be responsible for the NTPs adherence to 42 C.F.R. Part 8,
KRS Chapter 218A, 902 KAR 55:010 to 55:095, 908 KAR 1:370 and this
administrative regulation.
(5) The medical director may be the
program physician.
(6) There shall be one (1) medical
director or program physician on staff for every 300 clients, or fraction
thereof, enrolled in a NTP.
(7) The responsibilities of the medical
director or program physician(s) shall include:
(a) Assuring there is evidence of physiologic
dependence on narcotics for all clients admitted to the NTP;
(b) Assuring a history of addiction, or
that any exceptions to admissions criteria are approved by the SNA and
documented in the client's record before the first dose is administered;
(c) Assuring that appropriate medical
histories and physical examinations have been performed before the first dose
shall be administered;
(d) Assuring that appropriate laboratory
studies have been performed and have a documented review by the medical director
or program physician;
(e) Documenting, signing, or
countersigning all medical orders, within forty-eight (48) hours, that include
the first dose of narcotic drug or other approved medications;
(f) Documenting, signing, or
countersigning all subsequent medication orders within forty-eight (48) hours,
including dose increases and decreases, changes in frequency of take-home
doses, emergency situations, or special circumstances;
(g) Assuring that information on all
communicable diseases is communicated to all clients as required; and
(h) Assuring that a review and
cosignatures of all telephone or other verbal orders are documented within
forty-eight (48) hours of the order.
(8) The medical director or program
physician at the NTP shall:
(a) Supervise clinical staff responsible
for preparation and administering of the approved controlled substances; and
(b) Assure compliance with program
procedures and administrative regulations;
(9) The medical director or program
physician shall order all doses, all increases or decreases of doses of
medications or other approved drugs for the client, through the licensed NTP.
(10) Any verbal orders shall be given to
nursing or pharmacy staff and shall be cosigned by the medical director or
program physician within forty-eight (48) hours of the order’s receipt.
(11) The medical director or program
physician shall review all laboratory testing results required by the CSAT,
SNA, and testing indicated by the client's clinical record. Any specific
additional laboratory testing shall be ordered by the medical director or
program physician.
(12) The medical director or program
physician, in determining the client’s take-home medications, shall take into
consideration the items addressed in 42 C.F.R. Part 8 and shall comply with
Sections 10, 11, 12, 13 and 16 of this administrative regulation.
(13) NTPs shall provide dosing staff in
sufficient numbers to meet the needs of the clients during dosing hours. Dosing
staff shall:
(a) Hold a license as a registered nurse,
licensed practical nurse, or pharmacist; and
(b) Not be dually assigned as counselors.
(c) Dosing physicians and pharmacists
shall follow KRS 218A.180 related to labeling if preparing doses to be taken
outside the program site.
(14) Programs shall provide counselors
who shall have, at a minimum, a bachelors degree in a human services related
field and an alcohol and drug counselor certification from the Kentucky Board
of Alcohol and Drug Counselors or be actively engaged in the certification
process.
(15) There shall be one (1) counselor for
every forty (40) clients in the program.
Section 8. Physical Plant. (1) The
building used for the NTP shall meet requirements in 21 C.F.R. 1301.74(j) and
shall have space for the following operations:
(a) The waiting area shall be large
enough to accommodate the clients arriving for services.
(b) The waiting area shall be separated
from the dosing area to permit each client privacy and confidentiality at the
time of dosing.
(c) The dosing area shall be clean and sanitary,
shall accommodate the dosing staff, and shall contain the following:
1. A stainless steel sink;
2. Hot and cold running water;
3. A refrigerator for dosing supplies;
and
4. Pill-counting trays if tablets are
being used.
(2) Security and floor plan of the dosing
area may be unique to each program, except shall conform to the requirements in
21 C.F.R. 1301.72.
(3) The NTP shall make arrangements for
the facility to have two (2) restrooms which shall be handicapped accessible.
(4) The NTP shall assure that restrooms
available to clients to provide urine specimens are secure, private, clean, and
sanitary.
(5) The physical plant shall meet
building, fire, safety, and health standards specified by state and local
government laws and regulations.
(6) The physical plant shall be secured
by a local security company approved by the DEA and the SNA.
(7) There shall be a minimum of two (2)
panic buttons or similar devices for each NTP, one (1) in the reception area,
and one (1) in the dosing area.
(8) There shall be a telephone with an
outside line accessible in the dosing area.
(9) Internal security may be unique to
each NTP and shall meet the requirements of 21 C.F.R. 1301.74(b), (h), (i),
(j), (k); 1301.91; 1301.92 and shall be installed only after consultation with
the DEA Office and the SNA.
(10) Parking space at the clinic site
shall be adequate to accommodate the maximum number of clients expected to be
at the clinic site at one (1) time or have specific appointment schedules to
prevent the influx of clients that would be disruptive or unsafe to the surrounding
community.
(11) The NTP shall comply with all local
zoning and ordinance laws and requirements.
Section 9. Security and Control. (1) The
security and control segment of the NTP’s assessment procedure shall be
conducted quarterly by the program sponsor and dosing nurse supervisor or
pharmacist who shall assure that the requirements of 42 C.F.R. Part 8 are met.
Other items to be evaluated shall include:
(a) Security of the narcotic safe and the
building perimeter shall be checked with the contracted security company at the
facility location, quarterly. The security company may choose to test the
system by telephone.
(b) The safe shall be locked at all times
while staff are not obtaining or restocking controlled substances.
(c) Inventory reconciliation shall be
conducted, at a minimum of quarterly, and all reconciliation documents shall be
retained by the program for five (5) years.
(d) Five (5) percent or more of any
inventory discrepancies shall be reported to the SNA and the DEA offices within
forty-eight (48) hours of reconciliation.
(e) Dosing personnel shall count all new
bottles of narcotic tablets before removing any for client doses. Any
discrepancies shall be reported to the SNA, to the DEA and CSAT, and the
Department for Health Services’ Office of Drug Control, using the DEA 1305.12
(12/85) "Report of Theft or Loss of Controlled Substances" form,
within forty-eight (48) hours of the event.
(f) A system shall be devised to assure
the NTP completes the DEA biennial inventory of narcotic drugs on hand.
(g) Order forms for controlled
substances, the dosing records, and inventory reconciliation records shall
conform to 42 C.F.R. Part 8 and shall be maintained in a locked, secured area
separate from the storage site of the controlled substances.
(2) Utilization and effectiveness of
delivered services shall be reviewed by the program sponsor and medical
director annually for the following:
(a) Treatment slot utilization and cost
per slot;
(b) Staff-to-client ratio;
(c) Cost per counseling session; and
(d) Cost per client for other program
services.
(3) NTPs shall maintain written policies
to assure the confidentiality of all client records.
(4) Quarterly, the program sponsor shall
review a ten (10) percent random sample of client records for the following
information and assurances:
(a) Client signed the "Consent to
Treatment with an Approved Narcotic Drug," Form FDA 2635 (7/93);
(b) Client signed a release of
information form, developed by the NTP, which shall include:
1. Specific type of confidential
information to be obtained or released; and
2. Specific dates that the release is to
cover.
(c) If the program sponsor serves as a
counselor then the medical director shall review ten (10) percent of the
program sponsor’s client records for the same information and assurances as
cited above in paragraphs (a), (b)1 and 2 of this subsection.
(5) The NTP shall retain a copy of
internal assessment documents on file, which shall be available for review by
regulatory agencies for five (5) years.
(6) The NTP shall participate in the data
collection system as addressed in 908 KAR 1:300.
Section 10. Admission and Readmission
Policies. (1) The admitting physician for the NTP shall comply with the
admission requirements of 42 C.F.R. Part 8.
(2) Exceptions to the admission
requirements shall be those cited in 42 C.F.R. Part 8. Programs shall adhere to
the following for pregnant clients: In order for a NTP to admit or continue to
treat a client who is pregnant the medical director or program physician shall
first determine and document in the client’s record the following:
(a) The client is medically able to
participate in the program.
(b) If the medical director or program
physician does not accept the responsibility for providing prenatal care for
the term of the client's pregnancy, the medical director or program physician
shall refer the client to a primary care physician who practices obstetrics or
an obstetrician and shall inform the attending physician of the client's
participation in the NTP.
(c) If a pregnant client, the medical
director or program physician shall ensure that appropriate arrangements have
been made for the addiction-related medical care of both the client and the
child following the birth of the child.
(d) Maintenance treatment dosage levels
of pregnant clients shall be maintained at the lowest possible dosage level.
(e) The program shall ensure that the
following services are available for pregnant addicts and are a part of the
treatment plan:
1. The medical director or program
physician shall notify the pregnant client's primary care physician of any
changes in the client's treatment;
2. Nutritional counseling;
3. Parenting training including newborn
care, handling, health, and safety; and
4. Weekly full drug screen urinalysis;
(3) When a client applies for admission
to a NTP the client shall be required to sign a release of information that
authorizes a program to release or solicit information regarding the client's
status in any other substance abuse program.
(4) A client who has received treatment
and later voluntarily detoxified may be readmitted to a NTP without evidence to
support findings of current physiologic dependence, up to two (2) years after
discharge if the NTP attended is able to document prior treatment of six (6)
months or more, and the admitting medical director or program physician finds
readmission to the NTP to be medically justified.
(5) If a client seeks readmission to a
NTP after being administratively detoxified and the medical director or program
physician finds readmission to the NTP medically justified, the medical
director or program physician shall document such justification in the client's
medical record.
Section 11. Treatment Protocol. NTPs
shall comply with the following treatment phase system to achieve the goals of
reduced health problems, reduced criminal activity, increased productivity,
stabilization of family life and eventual drug free living.
(1) Entry phase. The first ninety (90)
days of treatment all clients shall adhere to the following:
(a) Clients shall be dosed with methadone
seven (7) days at the clinic site.
(b) Clients shall be provided weekly
counseling sessions to support the implementation of their treatment plan.
(c) Clients shall be provided HIV/AIDS
education and provided or referred for HIV pretest counseling and voluntary HIV
testing.
(d) Clients shall be oriented to
appropriate twelve (12) step programs such as narcotics anonymous or alcoholics
anonymous.
(e) During the entry phase the client
shall provide an observed urine sample one (1) time per week on a random basis.
(f) There shall be documentation in the
client record that treatment plans shall be reviewed and updated a minimum of
every thirty (30) days for three (3) months, every ninety (90) days thereafter.
(g) The medical director or program
physician shall sign the treatment plan.
(2) Phase one (1). In order for a client
to enter phase one (1) the client shall not have committed any program
infractions (dirty urine screens, disruptive behavior at the clinic site,
threats to staff or other clients, failure to attend scheduled dosing or
counseling appointments) for ninety (90) consecutive days.
(a) Once the client enters phase one (1)
the client shall attend clinic six (6) times each week for observed ingestion
of methadone and shall be eligible to receive a one (1) day take-home dose of
methadone.
(b) Clients shall be provided weekly
counseling sessions to support the implementation of their treatment plan.
(c) The client shall provide an observed
urine sample on a random basis at least weekly.
(d) Clients shall be encouraged to attend
an appropriate twelve (12) step program.
(e) There shall be documentation in the
client record that treatment plans shall be reviewed and updated every ninety
(90) days. This documentation shall include a report on the client's progress
in relation to his treatment plan.
(f) The medical director or program
physician shall sign the treatment plan.
(3) Phase two (2). In order for the
client to enter phase two (2) the client shall:
(a) Not have committed any program
infractions (dirty urine screens, disruptive behavior at the clinic site,
threats to staff or other clients, failure to attend scheduled dosing or
counseling appointments) for 180 consecutive days;
(b) Be pursuing gainful employment or
vocational training or attending school or be engaged in volunteer work, or be
attending parenting classes if they are a parent at home with children. Clients
with disabilities or other circumstances which might prohibit this requirement
may submit a written waiver request to the SNA justifying specific reasons for
the request;
(c) Have a treatment plan to meet any
special needs, including disabilities;
(d) Attend clinic five (5) times each
week for observed ingestion of methadone and be eligible to receive up to two
(2) days of take-home doses of methadone;
(e) Provide an observed urine sample
randomly on a monthly basis, or more frequently if their treatment plan
requires;
(f) Be provided monthly counseling
sessions, or more frequently if their treatment plan requires;
(g) Be encouraged to attend appropriate
self-help programs outside the clinic;
(h) Have documentation in the client
record that treatment plans shall be reviewed and updated every ninety (90)
days. This documentation shall include a report on the client's progress in
relation to the treatment plan; and
(i) Have their treatment plan signed by
the medical director or program physician.
(4) Phase three (3). In order for the
client to enter phase three (3) the client shall:
(a) Not have committed any program
infractions (dirty urine screens, disruptive behavior at the clinic site,
threats to staff or other clients, failure to attend scheduled dosing or
counseling appointments) for 270 consecutive days;
(b) Have met the same entry criteria
requirements as noted in phase two (2);
(c) Attend clinic three (3) times each
week for observed ingestion of methadone and be eligible to receive up to two
(2) days of take-home doses of methadone;
(d) Provide an observed urine sample on a
random basis, monthly, or more frequently if their treatment plan requires;
(e) Be provided monthly counseling
sessions, or more frequently if their treatment plan requires;
(f) Be encouraged to attend appropriate
self-help groups outside clinic;
(g) Have documentation in the client
record that treatment plans shall be reviewed and updated every ninety (90)
days. This documentation shall include a report on the client's progress in
relation to their treatment plan; and
(h) Have their treatment plan signed by
the medical director or program physician.
(5) Phase four (4). In order for the
client to enter phase four (4), the client shall have successfully completed
phase three (3) and adhered to the requirements of the maintenance treatment
program for two (2) consecutive years.
(a) Clients shall be dosed at the clinic
site two (2) days per week for observed ingestion of methadone and be eligible
for up to three (3) take-home doses of methadone.
(b) The number of counseling sessions
provided during this phase shall be based on the clinical judgement of the
program physician and program staff.
(c) Requirements in the area of urine
sample schedules, and treatment plan reviews remain the same as in subsection
(4) of this section.
(d) Prior to successful completion of
phase four (4), a plan shall be developed which shall assist the client toward
a drug free treatment regimen for continued support.
(e) The medical director or program
physician shall sign the treatment plan.
Section 12. Client Program Compliance. In
order for a client to remain in a NTP and to successfully move through the
treatment phases, clients shall be actively involved in the NTP by remaining in
good standing at the clinic or risk being administratively detoxified. If a
client has not complied with program policies:
(1) The client may be placed on a
behavioral contract for a minimum of sixty (60) days during any individual
program phase and shall lose all take-home dose privileges for sixty (60) days.
(2) If a client commits three (3)
infractions, the medical director or program physician and staff may choose to
move the client back in phases as part of the behavioral contract. The client
shall lose all take-home privileges during the contract period.
(3) Following the commitment of any
program infraction, the counseling staff shall assist the client in correcting
the problem behavior and document this effort in the client's treatment plan.
(4) If the client continues to experience
problems and breaks the behavioral contract, the client may be administratively
detoxified based on the recommendation of the program physician and the program
staff.
Section 13. Client Transfers. NTPs shall
accept clients transferring from another program within the state, if:
(1) The NTP accepting a client
voluntarily transferring from another NTP shall provide documentation that the
client's medical record and reason for the transfer was sought from the
client's previous NTP; and
(2) The client is in compliance with
readmission policies for clients who have been administratively detoxified.
(3) In order for the client to transfer
to another NTP, the following requirement shall be met:
(a) The NTP that client is leaving shall
forward all relevant client records to the program where the client is
transferring.
(b) The NTP shall provide documentation
that the client's medical record and reason for the transfer was sought from
the client's previous NTP and shall meet the admission criteria of this
administrative regulation.
(c) Clients who are Kentucky residents
and wish to transfer to another Kentucky-based program shall be reviewed by the
new program’s admission program physician or medical director on an individual basis
to determine their placement on the receiving program's client listing. The
review shall determine the client's need, program placement availability, and
the circumstances for the transfer request.
(d) Clients who are not Kentucky
residents shall transfer to a Kentucky program as a new admission or
"Entry Phase" as noted in this administrative regulation, Section
11(1) of this administrative regulation, unless other phase levels are approved
by the SNA.
Section 14. Client Appeal Procedures.
Decisions regarding a client's treatment by staff shall be subject to appeal by
the client. Each NTP shall:
(1) Develop an appeal procedure that
shall be approved by the SNA; and
(2) Have procedures that include a
provision that a central file of all client appeals be maintained at the NTP
for review by the SNA.
Section 15. Program Waiver Process. A NTP
may make an application to the SNA in order to seek waivers from any
requirement of this administrative regulation.
(1) This application for a waiver shall:
(a) Be in the form of a letter to the
SNA;
(b) Identify the specific sections of
this administrative regulation for which a waiver is being sought; and
(c) Give the rationale for the request.
(2) A copy of the waiver request and
response shall become part of the client's permanent record.
(3) Applications for waiver requests
shall be mailed to: Kentucky State Narcotic Authority, Division of Substance
Abuse, 275 East Main Street, Frankfort, Kentucky 40621.
(4) The SNA shall respond, in writing, to
the waiver request within fifteen (15) working days. The SNA shall provide
written justification for any waiver request that has been denied.
Section 16. Take-home Doses. (1) Under
emergency conditions a program may issue fourteen (14) consecutive days of take-home
doses without notification of CSAT. The NTP shall notify the SNA and request,
in writing, an exception to dosing procedures prior to administration of the
first emergency dose. This request shall include:
(a) The number of take-home doses
requested;
(b) The reason for the request; and
(c) The client's standing in program
phases, adherence to program policies, and the total length of time the client
has been enrolled at the NTP.
(2) The medical director or program
physician may grant an exception to the criteria for take-home dosages for any
of the following reasons subject to the limitations in this administrative
regulation and written approval from the SNA which shall be filed in the client
record:
(a) The client has a serious physical
disability which would prevent frequent visits to the program facility.
(b) The client is subject to an
exceptional circumstance such as acute illness, family crisis, or necessary
travel, where hardship would result from requiring exact compliance with the
step level schedule as noted in this administrative regulation. If a client
must travel out of the program area, the medical director or program physician
shall attempt to arrange for the client to receive his/her daily dosage at
another program in lieu of increasing take-home dosages.
(c) The medical director or program
physician shall not grant any exceptions during a calendar month which exceed
three (3) exceptions or ten (10) percent of the number of patients enrolled in
the program on the last day of the previous month, whichever is greater.
(d) The medical director or program
physician shall document in the client’s record the granting of any exception
and the facts justifying the exception. Each program shall also maintain a
separate record for all exceptions granted.
(e) The SNA shall not grant additional
exceptions, except in cases of medical emergency or natural disaster, such as
fire, flood, or earthquake.
(3) A NTP shall restrict a client’s
take-home dosage privileges by moving the client back at least one (1) step
level on the schedule for take-home dosages if the client’s urinalysis results
disclose the unauthorized presence of methadone, cocaine, opiates, amphetamines,
barbiturates, tetrahydrocannabinol, benzodiazepines, and any other drug(s) that
has been determined by the NTP or SNA to be abused in that NTP’s locality or
any other drug(s) that may have been abused by the client twice or more in a
sixty (60) day period.
(4) A NTP shall restrict a client’s
take-home dosage partially, by moving the client back on the take-home dosage
schedule, if the medical director or program physician concludes that the
client is no longer a suitable candidate or risk for take-home privileges as
presently scheduled.
(5) A NTP shall revoke a client’s
take-home privileges for not less than thirty (30) days and shall require the
client to ingest each dosage at the facility for any of the following reasons:
(a) The client’s urinalysis discloses an
absence of methadone, or methadone metabolite, and the medical director
confirms the accuracy of such analysis. This shall not be applicable to clients
whose daily dosage is twenty-five (25) milligrams or less.
(b) The client is discovered to be
misusing methadone, as defined in paragraph (e)3 of this subsection.
(c) The client attempts to register in
another NTP.
(d) The client alters or attempts to
alter a urinalysis.
(e) The client is not satisfactorily
adhering to the requirements of the NTP by the following:
1. The client has not complied with all
the rules of the NTP.
2. There is indication that the client
has repeatedly used drugs improperly.
3. There is indication, including
appropriate urinalysis results, that the client is misusing methadone. Misuse
of methadone includes sharing, giving away, selling, or trading one’s methadone
dosage, or not ingesting it in accordance with methadone maintenance treatment
program rules.
4. There is indication that the client is
selling, distributing, or otherwise involved with illicit drugs and their use.
5. The client is not participating in an
educational, vocational, or home-making activity.
(6) A client whose take-home privileges
were revoked or restricted may regain take-home privileges according to the
following schedule:
(a) Phase one (1) by satisfactory
adherence for at least thirty (30) days.
(b) Phase two (2) by satisfactory
adherence for at least thirty (30) days after regaining phase one (1)
privileges.
(c) Phase three (3) by satisfactory
adherence for at least thirty (30) days after regaining phase two (2) privileges.
(d) Phase four (4) by satisfactory
adherence for at least thirty (30) days after regaining phase three (3)
privileges.
(e) This section shall not be used to
circumvent the requirements of this administrative regulation. A client shall
not be advanced to a phase level pursuant to this section unless he has
previously been at that phase level after having satisfied the requirements of
this administrative regulation.
(7) If a NTP fails to comply with the
requirements in Sections 6, 7, 8, 9, 10, 11, 12, 13 or 16 of this
administrative regulation, the SNA may order the NTP to suspend all or part of
the take-home privileges for a period of thirty (30) days. The SNA shall notify
the NTP in writing, prior to any suspension, indicating the reasons for the
suspension:
(a) The NTP shall submit a plan of
correction to the SNA within ten (10) days of receipt of the SNA notification.
(b) If the NTP does not make the
corrections in the time specified, except has responded within the ten (10) day
time period indicating circumstances which the SNA has approved, the SNA may
extend the suspension for up to a second thirty (30) day period.
(c) If the NTP does not make the
necessary corrections or does not submit an acceptable plan of correction with
the SNA within the time frame specified in paragraph (a) of this subsection,
the SNA shall suspend the NTP’s take-home program until the necessary
corrections have been made.
(d) If the NTP is determined by the SNA
to not comply with Sections 6, 7, 8, 9, 11, 10, 11, 12, 13 or 16 of this
administrative regulation and is serving clients who meet the requirements in
Sections 10 and 11 of this administrative regulation, the SNA may restrict the
NTP’s take-home procedures to the provision of emergency take-homes according
to the requirements of Section 16 of this administrative regulation. This
restriction shall be in effect on a client-by-client basis until the NTP has
taken corrective actions that bring the program into compliance with Sections
6, 7, 8, 9, 10, 11, 12, 13 and 16 of this administrative regulation.
(8) Maintenance treatment shall be
discontinued within two (2) continuous years after the treatment is begun
unless, based upon the clinical judgement of the medical director or program
physician and staff which shall be recorded in the client’s record by the
medical director or program physician, the client’s status indicates that the
treatment should be continued for a longer period of time because
discontinuance from treatment would lead to a return to illicit opiate abuse or
dependence.
(9) Client status relative to continued
maintenance treatment shall be reevaluated at least annually after two (2)
continuous years of maintenance treatment and documented in the client’s record
by the medical director or program physician or maintenance treatment shall be
terminated.
(10) Documentation of the justification
for continued maintenance treatment required by this administrative regulation
shall indicate the client’s progress, or lack thereof, and future expectations
as required by this administrative regulation.
(11) Each NTP shall submit a specific
plan for a client's scheduled termination of maintenance treatment indicating a
period of maintenance before the scheduled termination.
(12) The termination plan shall include
dosage schedules, information on counseling, and any other patient support
which will be provided during withdrawal.
(13) Scheduled withdrawal shall be under
the immediate direction of the medical director or program physician and shall
be individualized.
(14) A client may voluntarily terminate
participation in a NTP even though termination may be against the advice of the
NTP.
(15) If the medical director or program
physician determines that the client’s continued participation in the program
creates a physically threatening situation for the staff or other clients, the
client’s participation may be terminated immediately.
(16) A client’s participation in a NTP
may be involuntarily terminated for cause.
(17) If a NTP utilizes disciplinary
proceedings which include involuntary termination for cause, the program shall
include in its protocol reasons and procedures for involuntarily terminating a
client’s participation in the program. The procedures shall provide for:
(a) Explanation to the client of when
participation may be terminated for cause;
(b) Client notification of termination;
(c) Client’s right to hearing; and
(d) Client’s right to representation.
(18) If the NTP elects not to terminate
for cause, the protocol shall state that clients shall not be involuntarily
terminated for cause except as provided in subsection (15) of this section.
(19) Except as noted in subsection (15)
of this section, either voluntary or involuntary termination shall take place
over a period of time not less than fifteen (15) days, unless:
(a) The medical director or program
physician deems it clinically necessary to terminate participation sooner and
documents why in the client’s record; or
(b) The client requests in writing a
shorter termination period.
Section 17. Client Rights. The following
shall apply:
(1) Clients shall have the right to
voluntary detoxification from the NTP.
(2) The client rights shall be posted in
conspicuous places in the facility.
(3) The client rights shall be signed by
the individual client attesting the client rights have been explained in such a
manner that they are understood. This signed copy shall be maintained in the
client's permanent medical record.
(4) Decisions regarding a client's
treatment by staff may be subject to appeal by the client.
(5) Each NTP shall develop an appeal
procedure that shall be approved by the SNA and shall include the following:
(a)
Each appeal procedure shall contain a detailed description of the NTP’s
pretermination fair hearing procedure. The appeal procedure shall provide that
a client has a right to a pretermination fair hearing if involuntarily
terminated from the program for cause if continued participation in the program
does not create a physically threatening situation for staff or others clients.
The procedure shall require:
1. Identification of reasons for
termination, as stated in the program rules, which may include:
a. Polydrug abuse;
b. Diversion of methadone;
c. Violence or threat of violence to
program staff or other clients in the program; or
d. Multiple registration.
2. Written notification to the client of
pending termination, containing:
a. Reasons for termination; and
b. Explanation of right to pretermination
fair hearing, which shall explain to the client that rights shall be exercised
within forty-eight (48) hours of written notice.
3. Provision for continuance of client’s
treatment status pending decision upon hearing;
4. Explanation of the client’s rights
during the hearing to:
a. Be represented at the hearing by a
person or attorney of their choice;
b. Call witnesses on their behalf, who
need not be under oath; and
c. Examine witnesses presented by the
NTP.
5. Release of medical information in the
client’s file to the client or the client’s representative at least forty-eight
(48) hours prior to the hearing;
a. Medical information requests by the
client shall be in the form of a signed consent to release of information.
b. Medical information to be released to
the client or client’s representative shall be provided by the physician in
charge of the client.
(b) The appeal procedure shall state
whether the client is entitled to a hearing before a panel or before a single
hearing officer. If the procedure states that the client is entitled to a
hearing before a panel, a single hearing officer may not be substituted for the
panel without the consent of the client. If a hearing before a panel, a
majority vote of the panel shall be necessary to terminate a person from the
NTP.
(c) The NTP shall select the hearing officer
or panel from impartial persons not directly involved with the client’s care.
(d) A hearing shall be scheduled within
ten (10) working days from the time the client requests a hearing.
(e) Unless the program procedures require
a higher standard of proof, a client’s participation in a program shall be
terminated for cause only after the hearing officer or panel finds by a
preponderance of the evidence presented that the reason stated in the notice
justifies termination.
(f) The hearing officer or panel shall
render a decision not later than the fifth working day following the hearing.
The NTP shall keep a permanent record of the proceeding. The permanent record
of the proceedings may be a tape recording. The decision shall be made in
writing and shall be based solely on the evidence presented at the hearing. The
decision shall include a summary of the proceedings and the formal findings and
conclusions of the hearing officer or panel.
1. A copy of the hearing decision shall
be provided to the client.
2. Copies of all written materials,
including all evidence introduced at the hearing, shall be retained for one (1)
year.
(g) A client may appeal an adverse action
of a hearing officer or panel by the following:
1. The client may appeal the decision by
filing an appeal with the Office of the Secretary, Cabinet for Health Services,
275 East Main Street, Frankfort, Kentucky 40621 within thirty (30) working days
of the decision.
2. The hearing shall be conducted in
accordance with the requirements of KRS Chapter 13B.
(6) All client appeals shall be
maintained at the NTP for review by the SNA for two (2) years.
Section 18. Protocol for the Change of a
NTP Location and the Protocol for Establishment of a Medication Station. The
protocol shall be current, detailed, specific, and complete to permit
evaluation by the SNA and to provide a basis for compliance inspections or
surveys.
(1) If a NTP voluntarily decides to
change its location or establish a medication station, the program shall
notify, in writing, the DEA, CSAT, the SNA and the Division of Licensing and
Regulation within the cabinet within ninety (90) days of the proposed
relocation. The written request to relocate shall include the following
information:
(a) The reason for the relocation;
(b) The relocation site;
(c) The proposed date of the relocation;
(d) Indicate any program changes that may
occur with the relocation; and
(e) If the NTP is within ninety (90)
miles of the original site, the NTP shall provide the following:
1. Any dosing procedural changes; and
2. Any drug distribution problems which
may occur due to the relocation.
(f) A medication station may be opened no
closer than forty-five (45) miles and no further than ninety (90) miles to the
main NTP.
1. The medication station shall obtain
its supply of approved controlled substance from the stocks of the main NTP.
2. The medication station shall provide
the following services:
a. Dosing; and
b. Urine screen collection.
3. The program sponsor shall develop a
system to prevent clients from dosing at the main NTP and the medication
station.
4. Any services provided at the
medication station other than those listed above shall have prior approval by
the CSAT and SNA.
(2) The CSAT, the DEA, and the SNA shall
agree that the NTP may establish a medication station or relocate to the
proposed relocation site. Written approval shall be forwarded to the NTP.
(3) If a NTP voluntarily decides to close
its operation, it shall notify the SNA, the DEA, CSAT and the Division of
Licensing and Regulation within ninety (90) days before the planned closure of
the program.
Section 19. Monitoring of NTPs. (1) The
SNA shall monitor NTPs to assure the health and safety of program clients and
the protection of the community at large. Monitoring visits shall be conducted
annually, or more frequently if indicated. The SNA may:
(a) Discontinue all take-home doses of
any approved controlled substance used in any NTP; or
(b) Discontinue the utilization of any
drug approved for use in narcotic treatment programs.
(2) Focused, unannounced monitoring
visits may be conducted more frequently and may occur in conjunction with the
CSAT and the DEA.
(3) Monitoring shall include:
(a) Inspection of the NTP licensing
status;
(b) Inspection of the status of all
applicable staff licenses and certificates;
(c) Inspection of the status of the NTP's
CSAT, DEA, and state licenses;
(d) Inspection of the NTP’s security
which shall include:
1. Building security, perimeter and
internal; and
2. Security of staff procedures in
receipt of narcotic drug, storage of narcotic drug, and handling of the drug in
preparation and dosing functions;
(e) Inspection of the records
maintenance, the inventory control procedures, and the internal inventory
reconciliation procedures;
(f) Inspection of the procedures the
program has in place to reduce the likelihood of drug diversion by program
clients and staff; and
(g) A random sample of doses prepared for
administration may be pulled for quantitative analysis and the SNA shall submit
to the program sponsor a receipt for any doses taken for analysis.
(4) Client records shall be reviewed for
the following:
(a) Client signed consent to treatment
with a controlled substance before the first dose was administered;
(b) Conformity with 42 C.F.R. Part 8
requirements for minimum medical evaluations;
(c) Conformity with 42 C.F.R. Part 8,
Sections 6(7) and 11(1)(e), (2)(c), (3)(e), (4)(d) of this administrative
regulation for urine drug screening requirements;
(d) Conformity with client record that
when the urine drug screen is positive for use of unapproved drugs, or is
negative for the approved controlled substance, the client is counseled and
suitable therapeutic action is taken by the treatment team, and the client’s
take-home doses have been discontinued for thirty (30) days. Except, the urine
drug screen shall not be used as the sole or primary reason for dismissing the
client from the NTP; and
(e) Treatment plans have been developed
and have been signed by the medical director or program physician in accordance
with this administrative regulation;
(f) All physician orders for medications,
doses, and dose changes and other treatments have been signed by the medical
director or program physician within forty-eight (48) hours of the order’s
receipt;
(g) No medications are administered
without the physician’s orders;
(h) The SNA shall monitor for all other
CSAT, DEA, or SNA administrative regulations; and
(i) Records shall be reviewed for
compliance with all treatment phases and waiver requests and approvals.
Section 20. Penalties. Penalties may be
issued by the SNA to NTPs that have violated CSAT and DEA requirements, and
this administrative regulation as follows:
(1) If a monitoring visit reveals
regulatory violations, the SNA shall, within ten (10) working days issue a
written report, which also shall be submitted to the CSAT and DEA, with a time
frame of thirty (30) days for the NTP to submit a plan of corrective action.
(2) If a plan of corrective action has
been submitted within the thirty (30) days and is acceptable, the SNA shall
notify the NTP in writing.
(3) A follow-up visit to verify that
corrective action has been made may be performed by the SNA.
(4) If the NTP has not filed a plan of
corrective action within thirty (30) days after receipt of the report, the NTP
shall be notified that its license shall be suspended for a period not to
exceed six (6) months or revoked.
(5) Upon notification of suspension or
revocation, the NTP may appeal the suspension or revocation in accordance with
Section 21 of this administrative regulation.
(6) The SNA shall immediately suspend or
revoke any narcotic treatment license if there is an emergency affecting the
health and safety of the client population or the community as a whole.
(7) The grounds which justify the
immediate suspension or revocation of a license shall be as follows:
(a) Take-home doses that fall outside
this administrative regulation without specific CSAT, DEA, or SNA approval
prior to issuance of the take-home dose;
(b) The allowable difference between the
labeled dosage of the approved controlled substance and the actual dosage as
determined by a drug assay shall be the United States Pharmacopeia error rate;
(c) More than five (5) percent of the
medical and dosing records reviewed are out of compliance with the
administrative regulations;
(d) Discrepancies in the inventory
reconciliation greater than five (5) percent;
(e) Continued dosing of clients prior to
completion of the intake procedures, including physical exam, except under SNA
approved circumstances;
(f) Evidence in the client’s record that
the physician is not in control of the client's treatment;
(g) Consistent dosing of clients before
the consent to treatment with controlled substances has been signed by the
client;
(h) Consistent failure to conduct the
required urine drug screening procedures on all drugs listed in Section 6(7) of
this administrative regulation;
(i) Failure to comply with Section 8(5)
of this administrative regulation; and
(j) Revocation of licensure.
(8) The SNA shall notify the CSAT
monitor, DEA, and the Department for Health Services Office of Drug Control at
the time revocation or suspension is taken in accordance with subsection (4) of
this section.
(9) Except in cases of emergencies
affecting the health and safety of the client population or the community as a
whole, an appeal shall stay any decision to suspend or revoke a license to
operate pending final decision of the secretary.
Section 21. Appeals. If the SNA takes
action to deny, suspend, or revoke a NTP license, the SNA shall notify the NTP
in writing stating the reasons for the adverse actions and the NTP’s right to
appeal.
(1) If the NTP believes an action by the
SNA is unfair, without reason, or unwarranted, the NTP may appeal the action in
writing to the Secretary, Cabinet for Health Services, Fourth (4th) Floor, 275
East Main Street, Frankfort, Kentucky 40621, within fifteen (15) days after
receipt of notice of action from the SNA.
(2) Upon receipt of the appeal, the
secretary, or his designee, shall notify the NTP in writing within fifteen (15)
days of the time and place of the hearing. The secretary, or his designee,
shall appoint a hearing officer to conduct the hearing in accordance with KRS
Chapter 13B.
(3) The hearing officer shall have
authority to issue subpoenas to compel the attendance of witnesses and the
production of documents to be used as evidence in hearings held pursuant to
this section.
(4) Based upon the record and upon the
information obtained at the hearing, the hearing officer shall affirm or
overturn the initial decision of the negative action. The decision of the
hearing officer shall be final. The NTP shall be notified in writing of the
decision of the hearing officer.
(5) If a NTP, whose license has been
suspended or revoked pursuant to Section 20(6) and (7) of this administrative
regulation, requests a hearing, the cabinet shall conduct the hearing within
ten (10) working days of receipt of the request from the NTP. The hearing may
be continued at the request of the NTP.
(a) The sole issue of the hearing shall
be whether one (1) or more grounds for suspension or revocation create an
immediate danger to the client population or the community as a whole.
(b) The cabinet shall render a decision
within five (5) working days of the hearing. If a decision is not rendered
within five (5) working days of the hearing, the NTP shall have its license
returned and be allowed to operate pending action on other regulatory
violations, if any.
(c) If the hearing officer decides within
five (5) working days of the close of the hearing that one (1) or more of the
grounds for suspension or revocation create an immediate danger to the client
population or the community as a whole, the license of the NTP shall be
suspended pending action of the cabinet to accept the plan of correction or
revoke the license.
(6) If suspension or revocation of the
license is upheld, the secretary’s, or his designee’s, notification shall
specify the date by which the NTP shall close.
(7) A NTP that continues to operate after
the closing date established by the secretary shall be subject to legal action
by the cabinet as provided by law.
Section 22. Material Incorporated by
Reference. (1) The following material is hereby incorporate by reference:
(a) Consent to Treatment with an Approved
Narcotic Drug form FDA 2635 (7/93);
(b) Report of Theft or Loss of Controlled
Substances form DEA 1305.12 (12/85); and
(c) US Official Order Forms-Schedules I
& II DEA form 222 (10/92) are hereby incorporated by reference.
(2) This material may be inspected,
copied, or obtained, subject to applicable copyright law, at the Department for
Mental Health and Mental Retardation Services, Division of Substance Abuse, 100
Fair Oaks Lane, Leestown Square, 4th Floor, Frankfort, Kentucky 40601, 8 a.m.
through 4:30 p.m., Monday through Friday. (22 Ky.R. 2512; Am. 23 Ky.R. 449;
eff. 8-21-96; 25 Ky.R. 935; 1384; eff. 12-16-98; 30 Ky.R. 1649; 1948; eff.
2-16-2004.)
